Renascience

Renascience EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Renascience (4889.T) as of Nov 19, 2026 is -58.22. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -125.20 — a change of -53.50% (higher).

EV/EBITDA

-58.22

YoY

-53.50%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Renascience is 2026 -58.22 . EV/EBITDA (Enterprise Value to EBITDA) of Renascience was 2025 -125.20 . It decreases by -53.50% higher compared to the previous year.

The Renascience EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2020
-131.03 JPY
Jan 1, 2021
-283.84 JPY
Jan 1, 2022
-105.86 JPY
Jan 1, 2023
-67.00 JPY
Jan 1, 2024
-89.86 JPY
Jan 1, 2025
-125.20 JPY
Jan 1, 2026
-58.22 JPY
The Renascience EV/EBITDA history
YEAREV/EBITDAYoY
-58.22-53.50%
-125.20+39.32%
-89.86+34.12%
-67.00-36.70%
-105.86-62.70%
-283.84+116.62%
-131.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

EV/EBITDA (Enterprise Value to EBITDA) of Renascience is -58.22 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of Renascience changed from -125.20 to -58.22, representing a -53.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Renascience since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Renascience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Renascience

All Key Metrics — Renascience